The B Cell Mutator AID Promotes B Lymphoid Blast Crisis and Drug Resistance in Chronic Myeloid Leukemia

Cancer Cell

Volumn 16, Issue 3, 2009, Pages 232-245

  Klemm, Lars ^a,b,c   Duy, Cihangir ^a,b,c   Iacobucci, Ilaria ^d   Kuchen, Stefan ^e   von Levetzow, Gregor ^a,b,c   Feldhahn, Niklas ^c   Henke, Nadine ^c   Li, Zhiyu ^e   Hoffmann, Thomas K ^c,h   Kim, Yong mi ^a,b   Hofmann, Wolf Karsten ^f   Jumaa, Hassan ^g   Groffen, John ^a,b   Heisterkamp, Nora ^a,b   Martinelli, Giovanni ^d   Lieber, Michael R ^a   Casellas, Rafael ^e   Müschen, Markus ^a,b,c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g MAX PLANCK INSTITUTE OF IMMUNOBIOLOGY AND EPIGENETICS   (Germany)

^h UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

CELLCYCLE

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; BCR ABL PROTEIN; IMATINIB; MUTAGENIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOBLAST; B LYMPHOCYTE; BLAST CELL CRISIS; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DISEASE COURSE; DNA REPAIR; DNA REPLICATION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; HUMAN CELL; LEUKEMIA CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

ANIMALS; B-LYMPHOCYTES; BLAST CRISIS; CELL LINE, TUMOR; CYTIDINE DEAMINASE; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; GREEN FLUORESCENT PROTEINS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LUCIFERASES, RENILLA; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MICE, SCID; MICE, TRANSGENIC; MUTATION; PIPERAZINES; PYRIMIDINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 69249236962     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2009.07.030     Document Type: Article

References (55)

1. Blagodatski A., Batrak V., Schmidl S., Schoetz U., Caldwell R.B., Arakawa H., and Buerstedde J.M. A cis-acting diversification activator both necessary and sufficient for AID-mediated hypermutation. PLoS Genet. 5 (2009) e1000332
2. Calabretta B., and Perrotti D. The biology of CML blast crisis. Blood 103 (2004) 4010-4022
3. Casellas R., Yamane A., Kovalchuk A.L., and Potter M. Restricting activation-induced cytidine deaminase tumorigenic activity in B lymphocytes. Immunology 126 (2009) 316-328
4. Chaudhuri J., Tian M., Khuong C., Chua K., Pinaud E., and Alt F.W. Transcription-targeted DNA deamination by the AID antibody diversification enzyme. Nature 422 (2003) 726-730
5. Chesi M., Robbiani D.F., Sebag M., Chang W.J., Affer M., Tiedemann R., Valdez R., Palmer S.E., Haas S.S., Stewart A.K., et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 13 (2008) 167-180
6. Crouch E.E., Li Z., Takizawa M., Fichtner-Feigl S., Gourzi P., Montaño C., Feigenbaum L., Wilson P., Janz S., Papavasiliou F.N., and Casellas R. Regulation of AID expression in the immune response. J. Exp. Med. 204 (2007) 1145-1156
7. Dedeoglu F., Horwitz B., Chaudhuri J., Alt F.W., and Geha R.S. Induction of activation-induced cytidine deaminase gene expression by IL-4 and CD40 ligation is dependent on STAT6 and NF-κB. Int. Immunol. 16 (2004) 395-404
8. Dickerson S.K., Market E., Besmer E., and Papavasiliou F.N. AID mediates hypermutation by deaminating single stranded DNA. J. Exp. Med. 197 (2003) 1291-1296
9. Di Noia J., and Neuberger M.S. Altering the pathway of immunoglobulin hypermutation by inhibiting uracil-DNA glycosylase. Nature 419 (2002) 43-48
10. Dörner T., Brezinschek H.P., Brezinschek R.I., Foster S.J., Domiati-Saad R., and Lipsky P.E. Analysis of the frequency and pattern of somatic mutations within nonproductively rearranged human variable heavy chain genes. J. Immunol. 158 (1997) 2779-2789
11. Dorsett Y., McBride K.M., Jankovic M., Gazumyan A., Thai T.H., Robbiani D.F., Di Virgilio M., San-Martin B.R., Heidkamp G., Schwickert T.A., et al. MicroRNA-155 suppresses activation-induced cytidine deaminase-mediated Myc-Igh translocation. Immunity 28 (2008) 630-638
12. Druker B.J., Guilhot F., O'Brien S.G., Kantarjian H., Deininger M.W., Silver R.T., Goldman J.M., Stone R.M., Cervantes F., Hochhaus A., et al. Five-year follow-up of patients receiving Imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355 (2006) 2408-2417
13. Druker B.J., Sawyers C.L., and Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344 (2001) 1038-1042
14. Faili A., Aoufouchi S., Guéranger Q., Zober C., Léon A., Bertocci B., Weill J.C., and Reynaud C.A. AID-dependent somatic hypermutation occurs as a DNA single-strand event in the BL2 cell line. Nat. Immunol. 3 (2002) 815-821
15. Feldhahn N., Henke N., Duy C., Klein F., von Levetzow G., Hofmann W.K., Jumaa H., and Müschen M. Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1-transformed acute lymphoblastic leukemia cells. J. Exp. Med. 204 (2007) 1157-1166
16. Gonda H., Sugai M., Nambu Y., Katakai T., Agata Y., Mori K.J., Yokota Y., and Shimizu A. The balance between Pax5 and Id2 activities is the key to AID gene expression. J. Exp. Med. 198 (2003) 1427-1437
17. Gourzi P., Leonova T., and Papavasiliou F.N. A role for activation-induced cytidine deaminase in the host response against a transforming retrovirus. Immunity 24 (2006) 779-786
18. Gourzi P., Leonova T., and Papavasiliou F.N. Viral induction of AID is independent of the interferon and the Toll-like receptor signaling pathways but requires NF-κB. J. Exp. Med. 204 (2007) 259-265
19. Kothapalli N., Norton D.D., and Fugmann S.D. A cis-acting DNA element targets AID-mediated sequence diversification to the chicken Ig light chain gene locus. J. Immunol. 180 (2008) 2019-2023
20. Lenz G., Nagel I., Siebert R., Roschke A.V., Sanger W., Wright G.W., Dave S.S., Tan B., Zhao H., Rosenwald A., et al. Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. J. Exp. Med. 204 (2007) 633-643
21. Li S., Ilaria Jr. R.L., Million R.P., Daley G.Q., and Van Etten R.A. The P190, P210, and P230 forms of BCR/ABL induce a similar chronic myeloid leukemia syndrome but have different lymphoid leukemogenic activity. J. Exp. Med. 189 (1999) 1399-1412
22. Liu M., Duke J.L., Richter D.J., Vinuesa C.G., Goodnow C.C., Kleinstein S.H., and Schatz D.G. Two levels of protection for the B cell genome during somatic hypermutation. Nature 451 (2008) 841-845
23. Longerich S., Orelli B.J., Martin R.W., Bishop D.K., and Storb U. Brca1 in immunoglobulin gene conversion and somatic hypermutation. DNA Repair (Amst.) 7 (2008) 253-266
24. Mathas S., Janz M., Hummel F., Hummel M., Wollert-Wulf B., Lusatis S., Anagnostopoulos I., Lietz A., Sigvardsson M., Jundt F., et al. Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma. Nat. Immunol. 7 (2006) 207-215
25. Melo J.V., and Barnes D.J. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat. Rev. Cancer 7 (2007) 441-453
26. Michael N., Shen H.M., Longerich S., Kim N., Longacre A., and Storb U. The E box motif CAGGTG enhances somatic hypermutation without enhancing transcription. Immunity 19 (2003) 235-242
27. Michor F., Hughes T.P., Iwasa Y., Branford S., Shah N.P., Sawyers C.L., and Nowak M.A. Dynamics of chronic myeloid leukaemia. Nature 435 (2005) 1267-1270
28. Muramatsu M., Kinoshita K., Fagarasan S., Yamada Y., Shinkai Y., and Honjo T. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102 (2000) 553-563
29. Muramatsu M., Sankaranand V.S., Anant S., Sugai M., Kinoshita K., Davidson N.O., and Honjo T. Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. J. Biol. Chem. 274 (1999) 18470-18476
30. Nutt S.L., Heavey B., Rolink A.G., and Busslinger M. Commitment to the B-lymphoid lineage depends on the transcription factor Pax5. Nature 401 (1999) 556-562
31. Okazaki I.M., Hiai H., Kakazu N., Yamada S., Muramatsu M., Kinoshita K., and Honjo T. Constitutive expression of AID leads to tumorigenesis. J. Exp. Med. 197 (2003) 1173-1181
32. Pasqualucci L., Neumeister P., Goossens T., Nanjangud G., Chaganti R.S., Kuppers R., and Dalla-Favera R. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 412 (2001) 341-346
33. Pasqualucci L., Bhagat G., Jankovic M., Compagno M., Smith P., Muramatsu M., Honjo T., Morse III H.C., Nussenzweig M.C., and Dalla-Favera R. AID is required for germinal center-derived lymphomagenesis. Nat. Genet. 40 (2008) 108-112
34. Pear W.S., Miller J.P., Xu L., Pui J.C., Soffer B., Quackenbush R.C., Pendergast A.M., Bronson R., Aster J.C., Scott M.L., and Baltimore D. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 92 (1998) 3780-3792
35. Petersen-Mahrt S.K., Harris R.S., and Neuberger M.S. AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification. Nature 418 (2002) 99-103
36. + ALL). Blood 110 (2007) 727-734
37. Rada C., and Milstein C. The intrinsic hypermutability of antibody heavy and light chain genes decays exponentially. EMBO J. 20 (2001) 4570-4576
38. Ramiro A.R., Jankovic M., McBride E., Eisenreich T.R., Chen J., Dickins R.A., Lowe S.W., Nussenzweig A., and Nussenzweig M.C. Role of genomic instability and p53 in AID-induced c-Myc-Igh translocations. Nature 440 (2006) 105-109
39. Revy P., Muto T., Levy Y., Geissmann F., Plebani A., Sanal O., Catalan N., Forveille M., Dufourcq-Labelouse R., Gennery A., et al. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell 102 (2000) 565-575
40. Robbiani D.F., Bothmer A., Callen E., Reina-San-Martin B., Dorsett Y., Difilippantonio S., Bolland D.J., Chen H.T., Corcoran A.E., Nussenzweig A., and Nussenzweig M.C. AID is required for the chromosomal breaks in c-myc that lead to c-myc/IgH translocations. Cell 135 (2008) 1028-1038
41. Rowley J.D. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243 (1973) 290-293
42. Sayegh C.E., Quong M.W., Agata Y., and Murre C. E-proteins directly regulate expression of activation-induced deaminase in mature B cells. Nat. Immunol. 4 (2003) 586-593
43. Shah N.P., Nicoll J.M., Nagar B., Gorre M.E., Paquette R.L., Kuriyan J., and Sawyers C.L. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor Imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2 (2002) 117-125
44. Shen H.M., Peters A., Baron B., Zhu X., and Storb U. Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes. Science 280 (1998) 1750-1752
45. Soverini S., Colarossi S., Gnani A., Rosti G., Castagnetti F., Poerio A., Iacobucci I., Amabile M., Abruzzese E., Orlandi E., et al. Contribution of ABL kinase domain mutations to Imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin. Cancer Res. 12 (2006) 7374-7379
46. Takahashi N., Miura I., Saitoh K., and Miura A.B. Lineage involvement of stem cells bearing the Philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of FACS and FISH. Blood 92 (1998) 4758-4763
47. Takizawa M., Tolarová H., Li Z., Dubois W., Lim S., Callen E., Franco S., Mosaico M., Feigenbaum L., Alt F.W., et al. AID expression levels determine the extent of cMyc oncogenic translocations and the incidence of B cell tumor development. J. Exp. Med. 205 (2008) 1949-1957
48. Teng G., Hakimpour P., Landgraf P., Rice A., Tuschl T., Casellas R., and Papavasiliou F.N. MicroRNA-155 is a negative regulator of activation-induced cytidine deaminase. Immunity 28 (2008) 621-629
49. Tsai A.G., Raghavan S.C., Müschen M., Hsieh C.L., and Lieber M.R. Human chromosomal translocations at CpG sites and a theoretical basis for their lineage and stage specificity. Cell 135 (2008) 1130-1142
50. Unniraman S., and Schatz D.G. Strand-biased spreading of mutations during somatic hypermutation. Science 317 (2007) 1227-1230
51. Verstegen M.M., Cornelissen J.J., Terpstra W., Wagemaker G., and Wognum A.W. Multilineage outgrowth of progenitor cells from individual chronic myeloid leukemia patients. Leukemia 13 (1999) 618-628
52. Virchow R. Weißes Blut. Frorieps Notizen 36 (1845) 151-156
53. Yu D., Allman D., Goldschmidt M.H., Atchison M.L., Monroe J.G., and Thomas-Tikhonenko A. Oscillation between B-lymphoid and myeloid lineages in Myc-induced hematopoietic tumors following spontaneous silencing/reactivation of the EBF/Pax5 pathway. Blood 101 (2003) 1950-1955
54. Yu K., Huang F.T., and Lieber M.R. DNA substrate length and surrounding sequence affect the activation-induced deaminase activity at cytidine. J. Biol. Chem. 279 (2004) 6496-6500
55. H rearrangement of immunoglobulin genes. Nat. Immunol. 7 (2006) 616-624